Immunotherapy-related toxicity in lung cancer: clinical characteristics and managing strategy

Worldwide,lung cancer is the most common malignancy and the leading cause of cancer-related death.After the era of chemotherapy,radiotherapy,and molecular-targeted therapy,the treatment of advanced lung cancer has entered a new era of immunotherapy,represented by immune checkpoint inhibitors(ICIs),including programmed cell death protein-1/programmed cell death protein ligand-1(PD-1/PD-L1)inhibitors and cytotoxic T-lymphocyte-associated antigen-4(CTLA-4)inhibitors.[1]However,patients treated with ICIs may experience unexpected systemic toxicities,some fatal.Thus,managing immunotherapy-related toxicity has become increasingly significant in patients with lung cancer.Here,we review the latest developments on the clinical features and management of immunotherapy-related toxicity in patients with lung cancer in order to promote the standardization of immunotherapy for lung cancer.